SCHEMBL5388561

SCHEMBL5388561

CCn1nc(CNCCC(F)(F)F)cc1-c1cccc(C(C)(C)NS(=O)(=O)CC(F)(F)F)c1

nearest known ligand 0.35

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC16A3 O15427 1/20 0.35
SLC16A1 P53985 1/20 0.35
MCTS1 Q9ULC4 1/20 0.35
EPHX2 P34913 4/20 0.33
PTGS2 P35354 3/20 0.33
SLC5A1 P13866 2/20 0.32
ELANE P08246 1/20 0.30
CCNT1 O60563 1/20 0.30
CCNA2 P20248 1/20 0.30
CDK2 P24941 1/20 0.30
CDK9 P50750 1/20 0.30
CDK5 Q00535 1/20 0.30
DYRK1A Q13627 1/20 0.30
CDK5R1 Q15078 1/20 0.30
DYRK2 Q92630 1/20 0.30
DYRK1B Q9Y463 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14408392 0.87 SLC16A3 (0.36) SLC16A3SLC16A1MCTS1SLC5A1ELANE
SCHEMBL5393515 0.85 SLC16A3 (0.37) SLC16A3SLC16A1MCTS1SLC5A1CCNT1
SCHEMBL8306100 0.83 SLC5A1 (0.33) SLC16A3SLC16A1MCTS1SLC5A1ELANE
SCHEMBL14408388 0.82 SLC5A1 (0.36) SLC16A3SLC16A1MCTS1SLC5A1ELANE
SCHEMBL5398783 0.79 ALDH1A1 (0.40) SLC16A3SLC16A1MCTS1
SCHEMBL5424671 0.79 CNR2 (0.39) SLC16A3SLC16A1MCTS1SLC5A1
SCHEMBL6903438 0.76 SCN9A (0.38)
SCHEMBL14717156 0.76 SCN9A (0.37) SLC16A3SLC16A1MCTS1CCNT1CCNA2
SCHEMBL5394536 0.76 SLC16A3 (0.33) SLC16A3SLC16A1MCTS1SLC5A1
SCHEMBL8305580 0.75 GRM5 (0.36) SLC5A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7271191-B2 Pyrazole derivatives as gamma-secretase inhibitors useful in the treatment of Alzheimer's disease MERCK SHARP & DOHME LTD. (GB) 2007-09-18 US disclosed
US-7271191-B2 Pyrazole derivatives as gamma-secretase inhibitors useful in the treatment of Alzheimer's disease MERCK SHARP & DOHME LTD. (GB) 2007-09-18 US disclosed
US-7271191-B2 Pyrazole derivatives as gamma-secretase inhibitors useful in the treatment of Alzheimer's disease MERCK SHARP & DOHME LTD. (GB) 2007-09-18 US disclosed
US-20060264474-A1 Pyrazole derivatives as gamma-secretase inhibitors useful in the treatment of alzheimer's disease MERCK SHARP & DOHME LTD. (GB) 2006-11-23 US disclosed
WO-2004089911-A1 PYRAZOLE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS USEFUL IN THE TREATMENT OF ALZHEIMER’S DISEASE MERCK SHARP & DOHME LIMITED (GB) 2004-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264474-A1 Pyrazole derivatives as gamma-secretase inhibitors useful in the treatment of alzheimer's disease BACE1, BACE2, PSEN1 SLC16A3 4845/4885SLC16A1 4830/4885MCTS1 4710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.